Cantor Fitzgerald Downgrades Tonix Pharma (TNXP) to Hold

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to Cantor Fitzgerald Downgrades Tonix Pharma (TNXP) to Hold

Tonix Pharma (TNXP) Says TNX-102 SL Phase 3 Did Not Meet Primary Endpoint in Fibromyalgia

September 6, 2016 7:11 AM EDT

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced preliminary topline results from its Phase 3 clinical study, AFFIRM, designed to evaluate the safety and efficacy of TNX-102 SL (cyclobenzaprine HCl sublingual tablets), 2.8 mg, in patients with fibromyalgia. AFFIRM was a 12-week randomized, double-blind, placebo-controlled trial of TNX-102 SL taken daily at bedtime, in which 519 participants were enrolled at 35 centers in the U.S. Fibromyalgia is a multi-symptom disorder that originates in the central nervous system and is characterized by widespread pain, non-restorative sleep, fatigue, and disability.

The AFFIRM data did not achieve... More